Granules India voluntarily recalls one batch of Naproxen Sodium tablets

Our Bureau Hyderabad | Updated on September 13, 2021

Move was on account of minor CGMP deviation

Granules USA, Inc., a wholly-owned foreign subsidiary of Granules India Ltd is voluntarily recalling one batch of Naproxen Sodium 220mg tablets at a retail level due to a minor “CGMP deviation”.

One batch has 11.4 million units of Naproxen tablets, out of which 0.9 million units that were released into the market were recalled. Financially, this does not have a material impact on the company.

“Granules manufactured and released a batch using Active Pharmaceutical Ingredient (API) from an alternate source prior to the final approval of a filed Prior Approval Supplement. We have since received the authorisation to use the API for this ANDA. There was absolutely no harm done at a patient level because the API used in the batch is from an FDA approved source.” GN Prashanth, Senior Vice President & Head Corporate Quality Assurance – Granules India Ltd said in a release.

Granules has not received any reports of adverse events that have been confirmed to be directly related to this recall as of the date, it added.

Published on September 13, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.

You May Also Like